Current developments of gene therapy in human diseases.

AAV CRISPR–Cas clinical trials gene therapy human diseases

Journal

MedComm
ISSN: 2688-2663
Titre abrégé: MedComm (2020)
Pays: China
ID NLM: 101769925

Informations de publication

Date de publication:
Sep 2024
Historique:
received: 10 09 2023
revised: 10 06 2024
accepted: 11 06 2024
medline: 19 8 2024
pubmed: 19 8 2024
entrez: 19 8 2024
Statut: epublish

Résumé

Gene therapy has witnessed substantial advancements in recent years, becoming a constructive tactic for treating various human diseases. This review presents a comprehensive overview of these developments, with a focus on their diverse applications in different disease contexts. It explores the evolution of gene delivery systems, encompassing viral (like adeno-associated virus; AAV) and nonviral approaches, and evaluates their inherent strengths and limitations. Moreover, the review delves into the progress made in targeting specific tissues and cell types, spanning the eye, liver, muscles, and central nervous system, among others, using these gene technologies. This targeted approach is crucial in addressing a broad spectrum of genetic disorders, such as inherited lysosomal storage diseases, neurodegenerative disorders, and cardiovascular diseases. Recent clinical trials and successful outcomes in gene therapy, particularly those involving AAV and the clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated proteins, are highlighted, illuminating the transformative potentials of this approach in disease treatment. The review summarizes the current status of gene therapy, its prospects, and its capacity to significantly ameliorate patient outcomes and quality of life. By offering comprehensive analysis, this review provides invaluable insights for researchers, clinicians, and stakeholders, enriching the ongoing discourse on the trajectory of disease treatment.

Identifiants

pubmed: 39156766
doi: 10.1002/mco2.645
pii: MCO2645
pmc: PMC11329757
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

e645

Informations de copyright

© 2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.

Déclaration de conflit d'intérêts

The authors have no conflict of interest to disclose.

Auteurs

Fanfei Liu (F)

Department of Ophthalmology West China Hospital Chengdu Sichuan China.

Ruiting Li (R)

State Key Laboratory of Biotherapy West China Hospital Chengdu Sichuan China.

Zilin Zhu (Z)

College of Life Sciences Sichuan University Chengdu Sichuan China.

Yang Yang (Y)

Department of Ophthalmology West China Hospital Chengdu Sichuan China.
State Key Laboratory of Biotherapy West China Hospital Chengdu Sichuan China.

Fang Lu (F)

Department of Ophthalmology West China Hospital Chengdu Sichuan China.

Classifications MeSH